Non-alcoholic Fatty Liver Diseases (NAFLD) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

MiR-18 regulates lipid metabolism of non-alcoholic fatty liver disease via IGF1
Cell Mol Biol (Noisy-le-grand). 2024 Apr 28;70(4):237-241. doi: 10.14715/cmb/2024.70.4.37.ABSTRACTWe aimed to illustrate the regulatory effect of miR-18 on the onset of non-alcoholic fatty liver disease (NAFLD). MiR-18 level in liver tissues collected from NAFLD patients and mice was detected. In vivo and in vitro influences of miR-18 on biochemical indexes, glucose tolerance and insulin resistance (IR) in NAFLD were determined. H&E staining was conducted to observe hepatic steatosis in NAFLD mice. The downstream target of miR-18 was finally detected by luciferase assay. MiR-18 was upregulated in liver tissues collecte...
Source: Mol Biol Cell - April 28, 2024 Category: Molecular Biology Authors: Hong Yang Bin Zhang Chun Yu Source Type: research

Integrating network pharmacology and experimental validation reveals therapeutic effects of D-mannose on NAFLD through mTOR suppression
In this study, network pharmacology followed by molecular docking analysis was utilized to identify potential targets of mannose against NAFLD, and the leptin receptor-deficient, genetically obese db/db mice was employed as an animal model of NAFLD to validate the regulation of D-mannose on core targets. As a result, 67 targets of mannose are predicted associated with NAFLD, which are surprisingly centered on the mechanistic target of rapamycin (mTOR). Further analyses suggest that mTOR signaling is functionally enriched in potential targets of mannose treating NAFLD, and that mannose putatively binds to mTOR as a core mec...
Source: Cell Research - April 28, 2024 Category: Cytology Authors: Sha Zhang Ying-Feng Gao Kai Zhang Guo-Rong Deng Guang-Xiang He Ping-Ping Gao Yi-Kang Yu Yuan Yuan Shu-Juan Xing Na Zhao Hong Zhang Yong-Chang Di-Wu Yi-Han Liu Bing-Dong Sui Zhe Li Jing Ma Chen-Xi Zheng Source Type: research

Relationship between changes in blood glucose, glycosylated hemoglobin [HbA1c], cholesterol, and triglyceride and changes in hepatic enzymes
Cell Mol Biol (Noisy-le-grand). 2024 Apr 28;70(4):23-28. doi: 10.14715/cmb/2024.70.4.4.ABSTRACTThe main risk factors for non-alcoholic fatty liver disease (NAFLD) are strongly associated with obesity, diabetes, hyperlipidemia, and metabolic syndrome. The best clinical evaluation of the liver is done through studying changes in liver enzymes' activity, especially alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase. Therefore, this study aimed to investigate the relationship between changes in factors such as blood glucose, cholesterol, glycosylated hemoglobin, and triglyceride and changes in hepat...
Source: Cellular and Molecular Biology - April 28, 2024 Category: Molecular Biology Authors: Mahboobeh Talebi Mehrdar Wei Lu Adel Rahanjam Source Type: research

MiR-18 regulates lipid metabolism of non-alcoholic fatty liver disease via IGF1
Cell Mol Biol (Noisy-le-grand). 2024 Apr 28;70(4):237-241. doi: 10.14715/cmb/2024.70.4.37.ABSTRACTWe aimed to illustrate the regulatory effect of miR-18 on the onset of non-alcoholic fatty liver disease (NAFLD). MiR-18 level in liver tissues collected from NAFLD patients and mice was detected. In vivo and in vitro influences of miR-18 on biochemical indexes, glucose tolerance and insulin resistance (IR) in NAFLD were determined. H&E staining was conducted to observe hepatic steatosis in NAFLD mice. The downstream target of miR-18 was finally detected by luciferase assay. MiR-18 was upregulated in liver tissues collecte...
Source: Cellular and Molecular Biology - April 28, 2024 Category: Molecular Biology Authors: Hong Yang Bin Zhang Chun Yu Source Type: research

Relationship between changes in blood glucose, glycosylated hemoglobin [HbA1c], cholesterol, and triglyceride and changes in hepatic enzymes
Cell Mol Biol (Noisy-le-grand). 2024 Apr 28;70(4):23-28. doi: 10.14715/cmb/2024.70.4.4.ABSTRACTThe main risk factors for non-alcoholic fatty liver disease (NAFLD) are strongly associated with obesity, diabetes, hyperlipidemia, and metabolic syndrome. The best clinical evaluation of the liver is done through studying changes in liver enzymes' activity, especially alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase. Therefore, this study aimed to investigate the relationship between changes in factors such as blood glucose, cholesterol, glycosylated hemoglobin, and triglyceride and changes in hepat...
Source: Mol Biol Cell - April 28, 2024 Category: Molecular Biology Authors: Mahboobeh Talebi Mehrdar Wei Lu Adel Rahanjam Source Type: research

Integrating network pharmacology and experimental validation reveals therapeutic effects of D-mannose on NAFLD through mTOR suppression
In this study, network pharmacology followed by molecular docking analysis was utilized to identify potential targets of mannose against NAFLD, and the leptin receptor-deficient, genetically obese db/db mice was employed as an animal model of NAFLD to validate the regulation of D-mannose on core targets. As a result, 67 targets of mannose are predicted associated with NAFLD, which are surprisingly centered on the mechanistic target of rapamycin (mTOR). Further analyses suggest that mTOR signaling is functionally enriched in potential targets of mannose treating NAFLD, and that mannose putatively binds to mTOR as a core mec...
Source: Biochemical and Biophysical Research communications - April 28, 2024 Category: Biochemistry Authors: Sha Zhang Ying-Feng Gao Kai Zhang Guo-Rong Deng Guang-Xiang He Ping-Ping Gao Yi-Kang Yu Yuan Yuan Shu-Juan Xing Na Zhao Hong Zhang Yong-Chang Di-Wu Yi-Han Liu Bing-Dong Sui Zhe Li Jing Ma Chen-Xi Zheng Source Type: research

Prevalence of Sarcopenia and Its Defining Components in Non-alcoholic Fatty Liver Disease Varies According to the Method of Assessment and Adjustment: Findings from the UK Biobank
This study examined the prevalence of sarcopenia and its defining components in adults with and without NAFLD and whether it varied by the method of muscle mass assessment [bioelectrical impedance (BIA) versus dual-energy X-ray absorptiometry (DXA)] and adjustment (height2 versus BMI). Adults (n = 7266) in the UK Biobank study (45–79 years) with and without NAFLD diagnosed by MRI, were included. Sarcopenia was defined by the 2018 European Working Group on Sarcopenia in Older People definition, with low appendicular skeletal muscle mass (ASM) assessed by BIA and DXA and adjusted for height2 or BMI. Overall, 21% of pa...
Source: Calcified Tissue International - April 28, 2024 Category: Orthopaedics Source Type: research

Inflammatory Protein Signatures as Predictive Disease-Specific Markers for Non-Alcoholic Steatohepatitis (NASH)
AbstractNon-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic disease worldwide, consisting of a broad spectrum of diseases such as simple steatosis (NAFL), non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma. Hepatic inflammation plays a key role in the pathophysiology of NAFLD. Inflammatory mediators such as cytokines and chemokines are considered as contributing factors to NAFLD development and progression. In the present study, we aimed to investigate the inflammatory protein signatures as predictive disease-specific markers for non-alcoholic fatty liver disease (NA...
Source: Inflammation - April 27, 2024 Category: Allergy & Immunology Source Type: research

Non –small cell lung cancer and immune checkpoint inhibitor therapy: does non-alcoholic fatty liver disease have an effect?
Immunotherapy based on the application of immune checkpoint inhibitors (ICIs) is one of the standard treatments for advanced non-small cell lung cancer (NSCLC). Non-alcoholic fatty liver Disease (NAFLD) has de... (Source: BMC Cancer)
Source: BMC Cancer - April 27, 2024 Category: Cancer & Oncology Authors: Yi Li, Bingxin Gong, Yusheng Guo, Weiwei Liu, Chao Chen, Shanshan Jiang, Feng Pan, Jiyu Song, Lian Yang and Guofeng Zhou Tags: Research Source Type: research

Efficacy and Safety of Fibroblast Growth Factor-21 Analogs for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis
Clin Pharmacol Ther. 2024 Apr 26. doi: 10.1002/cpt.3278. Online ahead of print.ABSTRACTFibroblast growth factor (FGF)-21 analogs are potential therapeutic candidates for metabolic dysfunction-associated steatohepatitis (MASH). This systematic review and meta-analysis aimed to assess the efficacy and safety of the FGF-21 analogs, efruxifermin, pegbelfermin, and pegozafermin for MASH treatment. A comprehensive systematic review and meta-analysis of randomized controlled trials from five major databases was conducted. Primary efficacy outcomes focused on liver histological improvement, while secondary efficacy outcomes encomp...
Source: Clinical Pharmacology and Therapeutics - April 26, 2024 Category: Drugs & Pharmacology Authors: Changhyeon Jeong Nayoung Han Nakyung Jeon Su-Jin Rhee Christine E Staatz Min-Soo Kim In-Hwan Baek Source Type: research

Triglyceride Glucose Index is Associated with Ultrasonographic Fatty Liver Indicator in Children and Adolescents with Non-alcoholic Fatty Liver Disease
CONCLUSION: TyG index was associated with the degree of hepatic steatosis, suggesting that it might be a useful tool for predicting the severity of pediatric NAFLD.PMID:38664989 | DOI:10.4274/jcrpe.galenos.2024.2024-2-5 (Source: JCRPE Journal of Clinical Research in Pediatric Endocrinology)
Source: JCRPE Journal of Clinical Research in Pediatric Endocrinology - April 26, 2024 Category: Endocrinology Authors: Bitgyeol Kim Hye Young Jin Jong Seo Yoon Eu Seon Noh Il Tae Hwang Source Type: research